Bartek Lipiński
机构: Uniwersytet Mikołaja Kopernika Student
每年引用次数
引用次数
引用: 119,005
H-指数: 152
I10-指数 : 479
出版物: 755
Mechanism of cadmium poisoning
Wiedermann D , Santavy F , Bartek J , Cernoch M
Lekarske listy 9 ( 2) 27 -30
1954
Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings
Eeles Ra , Stratton Mr , Easton Df , Warren W
Oncogene 8 ( 5) 1269 -1276
53
1993
ENHANCED PROTEIN STABILITY : A NOVEL MECHANISM OF D-TYPE CYCLIN OVER-ABUNDANCE IDENTIFIED IN HUMAN SARCOMA CELLS
Welcker M , Lukas J , Bartek J , Strauss M
Oncogene 13 ( 2) 419
45
1996
The retinoblastoma protein modulates expression of genes coding for diverse classes of proteins including components of the extracellular matrix.
Lukas J , Bartek J , Strauss M , Rohde M
Oncogene 12 ( 11) 2393
22
1996
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
J Bártková , B Vojtĕsek , J Lukás , J Bártek
Oncogene 6 ( 9) 1699 -1703
711
1991
Cellular localization and T antigen binding of the retinoblastoma protein.
J Bártek , D P Lane , B Vojtĕsek , R J Grand
Oncogene 7 ( 1) 101 -108
44
1992
Effects of tissue fixation conditions and protease pretreatment on immunohistochemical performance of a large series of new anti-keratin monoclonal antibodies: value in oncopathology.
B Vojtĕsek , R Pavlovská , A Rejthar , J Kovarík
Neoplasma 38 ( 4) 439 -446
4
1991
HLA-DR antigens on differentiating human mammary gland epithelium and breast tumours.
J Bártek , M Petřek , B Vojtěšek , J Bártková
British Journal of Cancer 56 ( 6) 727 -733
22
1987
Production and Characterization of Monoclonal Antibodies against
J Bártek , V Viklicky , V HOREJŠÍ , HANA VERLOVÁ
Folia biologica (Praha) 30
25
1984
UTILIZATION OF MONOCLONAL-ANTIBODIES FOR MAPPING OF ANTIGENIC DETERMINANTS ON THE TRANSFERRIN MOLECULE
V Viklicky , J Bártek
EOS-RIVISTA DI IMMUNOLOGIA ED IMMUNOFARMACOLOGIA 4 ( 4) 263 -267
5
1984
Mapping of antigenic sites on human transferrin by monoclonal antibodies
V Viklický , J Bártek , H Verlová , Pa Dráber
Monoclonal Antibodies and Cancer 4 261 -261
5
1983
PROBABILITY OF THE INCIDENCE OF SUITABLE DONOR-RECIPIENT PAIRS FOR TRANSPLANTATION THERAPY
K Lenhart , J Bártek , A Bártová , E Lenhartová
Acta Universitatis Palackianae Olomucensis 86 47 -47
1
1978
BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation.
J. Bartkova , E. Nacheva , J. Lukas , M.J.S. Dyer
Oncogene 9 ( 8) 2159 -2167
56
1994
Cytochemical and biochemical evidence of cathepsin B in malignant, transformed and normal breast epithelial cells
J. Taylor-Papadimitriou , E. Krepela , R.C. Hallowes , D. Rasnick
Journal of Cell Science 87 ( 1) 145 -154
29
1987
Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium.
I.M. Leigh , J. Taylor-Papadimitriou , E.B. Lane , A. Lewis
Journal of Cell Science 94 ( 3) 403 -413
219
1989
Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.
D. Lane , C.A. Midgley , B. Vojtesek , J. Bartek
Journal of Cell Science 101 ( 1) 183 -189
279
1992
A subclass of luminal epithelial cells in the human mammary gland, defined by antibodies to cytokeratins.
J. Taylor-Papadimitriou , E.M. Durban , R.C. Hallowes , J. Bartek
Journal of Cell Science 75 ( 1) 17 -33
121
1985
272 NQO1*2 POLYMORPHISM DOES NOT PREDICT OVERALL SURVIVAL IN HIGHER RISK MDS PATIENTS TREATED WITH 5-AZACYTIDINE
A. Moudra , M. Vancurová , V. Machalová , Z. Hodný
Leukemia Research 39
2015
NQO1 * 2 Polymorphism Predicts Overall Survival in Primary MDS Patients
A. Moudra , L. Minarik , M. Vančurová , Z. Hodný
Leukemia Research 55
2017
Long-distance inflammatory and genotoxic impact of cancer in vivo.
J. Bartek , M. Mistrik , J. Bartkova
Proceedings of the National Academy of Sciences of the United States of America 107 ( 42) 17861 -17862
8
2010